Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Carcinoid, Neuroendocrine Tumors
Interventions: EPO906 epothilone B; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 5
States / cities: Chicago, Illinois • Iowa City, Iowa • New Orleans, Louisiana + 2 more

Conditions: Breast Cancer, Gynecologic Cancer
Interventions: prasterone, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 280
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: metformin alone (Arm A), metformin (Arm B), rapamycin (Arm B); Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Scottsdale, Arizona • Baltimore, Maryland

Conditions: Type 1 Diabetes
Interventions: Continuous glucose monitor; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 8 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 11
States / cities: Beverly Hills, California • San Diego, California • Stanford, California + 7 more

Conditions: Diabetic Foot Ulcer, Diabetic Foot
Interventions: Lifestyle-based intervention by an occupational therapist; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin glargine, insulin degludec, metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 18
States / cities: Inglewood, California • Los Angeles, California • Redlands, California + 14 more

Conditions: Type 2 Diabetes Mellitus
Interventions: LGD-6972, Placebo (Captisol®); Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Upper Respiratory Infection, Hypertension, Diabetes
Interventions: Spanish speaker level; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Fresno, California

Conditions: Craniopharyngioma, Hypothalamic Obesity
Interventions: Syntocinon, Placebo (for Syntocinon); Drug
Lead sponsor: Shana McCormack, MD; Other
Eligibility: 10 Years to 35 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Solid Tumor, Adult, Breast Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Ovarian Cancer
Interventions: CX-2009; Drug
Lead sponsor: CytomX Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 10 more

Conditions: Type 2 Diabetes Mellitus (T2DM), Sarcopenia, Obesity, Muscle Loss, Older Adults
Interventions: Calcium-HMB Plus Vitamin D3, Matching placebo; Dietary Supplement · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 65 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Edema
Interventions: mild compression diabetic sock, Standard diabetic sock; Device
Lead sponsor: Rosalind Franklin University of Medicine and Science; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: Hypothyroidism
Interventions: North Star, Levothyroxine; Drug
Lead sponsor: Neuvosyn Laboratories, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 31
States / cities: Birmingham, Alabama • Canoga Park, California • Greenbrae, California + 23 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Diabetes self-management program for Hispanics and their families, General health educational program for Hispanics and their families; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Growth Hormone Deficiency (GHD)
Interventions: MOD-4023; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Graves' Disease, Graves Disease
Interventions: Efgartigimod PH20 SC, Placebo PH20 SC; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 29
States / cities: Carlsbad, California • Orange, California • Pasadena, California + 24 more

Conditions: Diabetes, Lipodystrophy, Hyperlipidemia
Interventions: Metreleptin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Months to 98 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes
Interventions: RO 205-2349; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 14
States / cities: Hollywood, Florida • Durham, North Carolina • Morrisville, North Carolina + 9 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, LY2922470; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Chula Vista, California • Eatontown, New Jersey • New York, New York + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Office Guidelines Applied to Practice (Office-GAP) + Mobile text messaging, Mobile text messaging; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Pancreatic Cancer, Ductal Adrenocarcinoma, Exocrine Pancreatic Cancer
Interventions: PCI-27483, Gemcitabine; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 17
States / cities: Scottsdale, Arizona • Anaheim, California • Titusville, Florida + 13 more

Conditions: Breast Cancer, DCIS
Interventions: THRIVE Online PAT Program; Behavioral
Lead sponsor: Joanna Arch; Other
Eligibility: 21 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Type 1 Diabetes Mellitus
Interventions: Lisofylline; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 45 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Pancreas Cancer, Biliary Tract Cancer
Interventions: Alcohol Injection, Placebo Injection; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer

Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes

Adapting Lifestyle Offloading for DFUs

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

Doctor-Patient Communication in Spanish

Intranasal Oxytocin in Hypothalamic Obesity

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide

Mild Compression Sock for Control of Lower Extremity Edema in Individuals With Diabetes

A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism

A Family-Based Diabetes Intervention for Hispanic Adults in an Emerging Community

Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy

Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus

A Study of Multiple Doses of LY2922470 in Participants With Diabetes

Decreasing Cardiovascular Risk for Patients With Diabetes

Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence

Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus

Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control